Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

Abstract

BACKGROUND Plasma concentrations of tenofovir increase when the drug is coadministered with some ritonavir-boosted protease inhibitors (PI/r). We hypothesized that tenofovir disoproxil fumarate (TDF)-treated patients taking PI/r-based regimens would have a greater decline in renal function than patients receiving nonnucleoside reverse-transcriptase… (More)
DOI: 10.1086/524061

Topics

3 Figures and Tables

Cite this paper

@article{Goicoechea2008GreaterTR, title={Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.}, author={Miguel Goicoechea and Shanshan Liu and Brookie M. Best and Shelly Sun and Sonia Jain and Carol A. Kemper and M. Witt and Catherine A Diamond and Richard Haubrich and Stan Gee Louie}, journal={The Journal of infectious diseases}, year={2008}, volume={197 1}, pages={102-8} }